Actemra (Genentech/Roche) success in ADACTA study in RA

Data from the ADACTA study showed that adult Rheumatoid Arthritis (RA) patients who received Actemra (tocilizumab) from Genentech/Roche as single-agent therapy (without other DMARDs) experienced a significantly greater improvement in disease activity (DAS28 score reduction) after 24 weeks compared to patients who received adalimumab as single-agent therapy. The results of ADACTA will be presented on Friday at the annual European League Against Rheumatism (EULAR) conference in Berlin.Results from ADACTA showed that after 24 weeks of treatment, adult patients with severe active RA and intolerance or inadequate response to MTX: 1.achieved a mean improvement in disease activity (DAS28 score reduction) of 3.3 with Actemra versus 1.8 with adalimumab, 2. had a DAS28 remission rate of 40 percent with Actemra versus 11 percent with adalimumab (DAS28 <2.6), 3.achieved acr20 50 and 70 responses of 65 percent 47 percent and 33 percent with actemra versus 49 percent 28 percent and 18 percent with adalimumab.>